A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature

Oncogene

Volumn 32, Issue 42, 2013, Pages 5026-5037

  Russo, N ^a   Wang, X ^b,c   Liu, M ^a   Banerjee, R ^a   Goto, M ^a   Scanlon, C ^a   Metwally, T ^a   Inglehart, R C ^a   Tsodikov, A ^d   Duffy, S ^b   Van Tubergen, E ^a   Bradford, C ^d   Carey, T ^d   Wolf, G ^d   Chinnaiyan, A M ^b,c   D'silva, N J ^a,b,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

L23; Proliferation; Tumor antigen

Indexed keywords

L23 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; BIOPANNING; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; GENE OVEREXPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC ANALYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNE SYSTEM; KERATINOCYTE; MOLECULAR CLONING; ONCOGENE; PRIORITY JOURNAL; RECEPTOR UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; AUTOANTIBODIES; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURFACE DISPLAY TECHNIQUES; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; KERATINOCYTES; MICE; MICE, NUDE; NIH 3T3 CELLS; ONCOGENES; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RIBOSOMAL PROTEINS; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84886097621     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.532     Document Type: Article

References (43)

1. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
4. Li G, Ali SA, McArdle SE, Mian S, Ahmad M, Miles A et al. Immunity to tumour antigens. Curr Pharm Des 2005; 11: 3501-3509. (Pubitemid 41300756)
5. Laheru DA, Pardoll DM, Jaffee EM. Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther 2005; 4: 1645-1652. (Pubitemid 41685298)
6. Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810-11813. (Pubitemid 26014201)
7. Chen YT, Güre AO, Tsang S, Stockert E, Jäger E, Knuth A et al. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998; 95: 6919-6923. (Pubitemid 28278082)
8. Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-1918. (Pubitemid 27113936)
9. Stockert E, Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187: 1349-1354. (Pubitemid 28189124)
10. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249: 386-390.
11. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 1224-1235. (Pubitemid 41345944)
12. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J et al. Human anti-self antibodies with high specificity from phage display libraries. Embo J 1993; 12: 725-734. (Pubitemid 23073720)
13. Bonnycastle LL, Mehroke JS, Rashed M, Gong X, Scott JK. Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J Mol Biol 1996; 258: 747-762. (Pubitemid 26150878)
14. Wanzel M, Wanzel M, Russ AC, Kleine-Kohlbrecher D, Colombo E, Pelicci PG et al. A ribosomal protein L23-nucleophosmin circuit coordinates Mizl function with cell growth. Nat Cell Biol 2008; 10: 1051-1061.
15. Liu F, Li Y, Yu Y, Fu S, Li P. Cloning of novel tumor metastasis-related genes from the highly metastatic human lung adenocarcinoma cell line Anip973. J Genet Genomics 2007; 34: 189-195. (Pubitemid 46694389)
16. Shi Y, Zhai H, Wang X, Han Z, Liu C, Lan M et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. Exp Cell Res 2004; 296: 337-346. (Pubitemid 38624654)
17. Bigler LR, Streckfus CF, Copeland L, Burns R, Dai X, Kuhn M et al. The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med 2002; 31: 421-31. (Pubitemid 34973690)
18. Leethanakul C, Patel V, Gillespie J, Shillitoe E, Kellman RM, Ensley JF et al. Gene expression profiles in squamous cell carcinomas of the oral cavity: use of laser capture microdissection for the construction and analysis of stage-specific cDNA libraries. Oral Oncol 2000; 36: 474-483. (Pubitemid 30645984)
19. Dybwad A, Førre O, Kjeldsen-Kragh J, Natvig JB, Sioud M. Identification of new B cell epitopes in the sera of rheumatoid arthritis patients using a random nanopeptide phage library. Eur J Immunol 1993; 23: 3189-3193. (Pubitemid 23353768)
20. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell 2009; 16: 369-377.
21. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 2004; 279: 44475-44482. (Pubitemid 39430853)
22. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 2004; 24: 7654-7668. (Pubitemid 39121491)
23. Dai MS, Shi D, Jin Y, Sun XX, Zhang Y, Grossman SR et al. Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem 2006; 281: 24304-24313. (Pubitemid 44274203)
24. Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 2004; 24: 7669-7680. (Pubitemid 39121492)
25. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
26. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-1157.
27. Brakenhoff RH. Cancer. Another NOTCH for cancer. Science 2011; 333: 1102-1103.
28. Patel V, Hood BL, Molinolo AA, Lee NH, Conrads TP, Braisted JC et al. Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res 2008; 14: 1002-1014. (Pubitemid 351302545)
29. Philip M, Schietinger A, Schreiber H. Ribosomal versus non-ribosomal cellular antigens: factors determining efficiency of indirect presentation to CD4+ T cells. Immunology 2010; 130: 494-503.
30. Monach PA, Meredith SC, Siegel CT, Schreiber H. A unique tumor antigen produced by a single amino acid substitution. Immunity 1995; 2: 45-59.
31. Matsutake T, Srivastava PK. The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci USA 2001; 98: 3992-3997. (Pubitemid 32249886)
32. Beck-Engeser GB, Monach PA, Mumberg D, Yang F, Wanderling S, Schreiber K et al. Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens. J Exp Med 2001; 194: 285-300.
33. Koga M, Shichijo S, Yamada A, Ashihara J, Sawamizu H, Kusukawa J et al. Identification of ribosomal proteins S2 and L10a as tumor antigens recognized by HLA-A26-restricted CTL. Tissue Antigen 2003; 61: 136-145. (Pubitemid 36549599)
34. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibodybased immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28: 4390-4399.
35. Bsoul SA, Huber MA, Terezhalmy GT. Squamous cell carcinoma of the oral tissues: a comprehensive review for oral healthcare providers. J Contemp Dent Pract 2005; 6: 1-16. (Pubitemid 41810916)
36. Neville BW et al. Oral and Maxillofacial Pathology. 2nd edn (WB Saunders), 2002 337-367.
37. Nemeth Z, Velich N, Bogdan S, Ujpál M, Szabó G, Suba ZS. The prognostic role of clinical, morphological and molecular markers in oral squamous cell tumors. Neoplasma 2005; 52: 95-102.
38. Chen G, Wang X, Yu J, Varambally S, Yu J, Thomas DG et al. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res 2007; 67: 3461-3467. (Pubitemid 46724887)
39. Banerjee R, Mani RS, Russo N, Scanlon CS, Tsodikov A, Jing X et al. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 2011; 30: 4339-4349.
40. Goto M, Mitra RS, Liu M, Lee J, Henson BS, Carey T et al. Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res 2010; 16: 65-76.
41. Mitra RS, Zhang Z, Henson BS, Kurnit DM, Carey TE, D'Silva NJ. Rap1A and rap1B rasfamily proteins are prominently expressed in the nucleus of squamous carcinomas: nuclear translocation of GTP-bound active form. Oncogene 2003; 22: 6243-6256. (Pubitemid 37281654)
42. Mitra RS, Goto M, Lee JS, Maldonado D, Taylor JM, Pan Q et al. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res 2008; 68: 3959-3969.
43. Zhang Z, Mitra RS, Henson BS, Datta NS, McCauley LK, Kumar P et al. Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol 2006; 168: 585-596. (Pubitemid 43271156)